Elevation in Inflammatory Serum Biomarkers Predicts Response to Trastuzumab-Containing Therapy
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to trastuzumab-containing therapy. Therefore, there remains an urgent and unmet clinical need for the development of predictive biomarkers for trastuzumab response. Recently, several lines of evidence have demonstrated that the inflammatory tumor microenvironment is a major contributor to therapy resistance in breast cancer. In order to explore the predictive value of inflammation in breast cancer patients, we measured the inflammatory biomarkers serum ferritin and C-reactive protein (CRP) in 66 patients immediately before undergoing trastuzumab-containing therapy and evaluated their progression-free and overall survival. The elevation in pre-treatment serum ferritin (>250 ng/ml) or CRP (>7.25 mg/l) was a significant predictor of reduced progression-free survival and shorter overall survival. When patients were stratified based on their serum ferritin and CRP levels, patients with elevation in both inflammatory biomarkers had a markedly poorer response to trastuzumab-containing therapy. Therefore, the elevation in inflammatory serum biomarkers may reflect a pathological state that decreases the clinical efficacy of this therapy. Anti-inflammatory drugs and life-style changes to decrease inflammation in cancer patients should be explored as possible strategies to sensitize patients to anti-cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 1×
“Aside from their ability to induce therapy resistance in cancer cells, the presence and activation of inflammatory cells within the tumor can affect vascular structure and permeability, and thus drug distribution within the tumor [13,14,33].”
BackgroundWeight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women
Tchernof, A., Nolan, A., Sites, C. K., Ades, P. A., & Poehlman, E. T. (2002) · Circulation · doi:10.1161/hc0502.103331 · Cited by 541
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541 · cited 3×
“Also, inhibition of macrophage-derived cathepsins in vivo increases the efficacy of chemotherapeutic agents against primary and metastatic sites [12].”
BackgroundSerum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
Cohen, L. A., Gutierrez, L., Weiss, A., Leichtmann-Bardoogo, Y., Zhang, D.-L., Crooks, D. R., Sougrat, R., Morgenstern, A., Galy, B., Hentze, M. W., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253815 · Cited by 452
Serum Ferritin and Risk of the Metabolic Syndrome in U.S. Adults
Jehn, M., Clark, J. M., & Guallar, E. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2422 · Cited by 443 · cited 1×
“) and genetic factors [21,22,23,24,25].”
Association between dietary fiber and serum C-reactive protein
Ma, Y., Griffith, J. A., Chasan-Taber, L., Olendzki, B. C., Jackson, E., Stanek, E. J., Li, W., Pagoto, S. L., Hafner, A. R., & Ockene, I. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.760 · Cited by 396 · cited 1×
“) and genetic factors [21,22,23,24,25].”
Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses
Zhang, Z., Zhang, F., An, P., Guo, X., Shen, Y., Tao, Y., Wu, Q., Zhang, Y., Yu, Y., Ning, B., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330324 · Cited by 250
Secretion of Ferritin by Rat Hepatoma Cells and Its Regulation by Inflammatory Cytokines and Iron
Tran, T. N., Eubanks, S. K., Schaffer, K. J., Zhou, C. Y. J., & Linder, M. C. (1997) · Blood · doi:10.1182/blood.v90.12.4979 · Cited by 236
An iron regulatory gene signature predicts outcome in breast cancer
Miller, L. D., Coffman, L. G., Chou, J. W., Black, M. A., Bergh, J., D'Agostino, R., Torti, S. V., & Torti, F. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1870 · Cited by 202 · cited 1×
“Recently, the ferritin receptor, Scara5, has been included in a prognostic gene panel for breast cancer indicating that the capability of cancer cells to uptake ferritin may confer a survival or proliferative advantage [34].”
Background
Cited by
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Iron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
“High serum FT levels in cancer patients are associated with more aggressive clinical course and poor treatment response but it is unknown whether high FT actively contributes to disease progression or is a biomarker reflecting systemic immune activation (168), which is well-known to be associated with a poor prognosis…”
BackgroundHepcidin and ferritin blood level as noninvasive tools for predicting breast cancer
Orlandi, R., De Bortoli, M., Ciniselli, C. M., Vaghi, E., Caccia, D., Garrisi, V., Pizzamiglio, S., Veneroni, S., Bonini, C., Agresti, R., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt490 · Cited by 74
Metadata
- Authors
- Alkhateeb, A. A., Leitzel, K., Ali, S. M., Campbell-Baird, C., Evans, M., Fuchs, E.-M., Köstler, W. J., Lipton, A., & Connor, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-26
- Volume
- 7
- Issue
- 12
- Pages
- e51379
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2028156437
- Cited by
- 35
- References
- 11
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.